Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

NCT01658943 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

137

Enrollment

NIH

Sponsor class

Conditions

Pancreatic Acinar Cell Carcinoma
Pancreatic Ductal Adenocarcinoma
Recurrent Pancreatic Carcinoma
Stage IV Pancreatic Cancer

Interventions

DRUG: Akt Inhibitor MK2206
DRUG: Fluorouracil
DRUG: Oxaliplatin
DRUG: Selumetinib

Sponsor

National Cancer Institute (NCI)